October 25, 2018 04:37 AM EDT
Pharma

Ab­b­Vie is go­ing for it in cys­tic fi­bro­sis. But why are they buy­ing the weak Gala­pa­gos port­fo­lio in a $245M deal?

John Carroll

Editor & Founder

Ab­b­Vie took a hard look at some weak da­ta for Gala­pa­gos’ $GLPG dou­ble and triple for cys­tic fi­bro­sis — and de­cid­ed to buy the lot. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times